Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC
Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, and SOTIO, a biotechnology company owned by the PPF Group, announce that the first patient has been dosed with ONCOS-102 in the SP015 phase I/II clinical trial in patients with prostate cancer, combining the Company’s immune-priming adenovirus ONCOS-102, with SOTIO’s DCVAC/PCa, an active cellular immunotherapy.The first patient has been dosed with ONCOS-102 at the Motol University Hospital in Prague, by the